Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Dual Infection by Liu, Zhihua & Hou, Jinlin
Int. J. Med. Sci. 2006, 3  57
International Journal of Medical Sciences 
ISSN 1449-1907 www.medsci.org 2006 3(2):57-62 
©2006 Ivyspring International Publisher. All rights reserved 
Review 
Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Dual Infection 
Zhihua Liu, and Jinlin Hou  
Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China  
Corresponding address: Jinlin Hou, M.D, Hepatology Unit and Dept. of Infectious Diseases, Nanfang Hospital, Guangzhou 510515, 
China. email: jlhou@fimmu.com Tel: 86-20-61641941 Fax: 86-20-87714940 
Received: 2005.12.30; Accepted: 2006.03.15; Published: 2006.04.01 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases 
worldwide. Because the two hepatotropic viruses share same modes of transmission, coinfection with the two viruses is 
not uncommon, especially in areas with a high prevalence of HBV infection and among people at high risk for 
parenteral infection. Patients with dual HBV and HCV infection have more severe liver disease, and are at an increased 
risk for progression to hepatocellular carcinoma (HCC). Treatment of viral hepatitis due to dual HBV/HCV infection 
represents a challenge. 
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1.  Introduction 
Approximately 350 million people are infected with 
HBV worldwide, and the World Health Organization 
(WHO) estimates that approximately 170 million people 
are infected with HCV. HBV and HCV infection account 
for a substantial proportion of liver diseases worldwide. 
Because the two hepatotropic viruses share same modes 
of transmission, coinfection with the two viruses is not 
uncommon, especially in areas with a high prevalence of 
HBV infection and among people at high risk for 
parenteral infection. The exact number of patients infected 
with both HCV and HBV is unknown. 
2.  Epidemiology 
Dual infection with HBV and HCV is not uncommon 
in geographic areas where a high endemic level of both 
infections is reported, such as Southeast-Asia and 
Mediterranean. In general, the prevalence is around 10-
20% in patients with chronic HBV infection (see table1) [1-
10], and 2-10% of anti-HCV-positive patients to have 
markers of HBV infection. In addition to chronic liver 
diseases, coinfection of HBV and HCV is frequently found 
in injection drug users (IDU, 42.5%) [11], patients on 
hemodialysis (3.7%) [12], patients undergoing organ 
transplantation (8%) [13], HIV-positive individuals (66%) 
[14], and beta-thalassemia patients (10%) [15], which 
means that those are the high risk population for infection 
of HBV and HCV concurrently. A multicenter study in 
Italy [16] showed that the subjects with dual HBV and 
HCV infection were more likely to be older than 42 years, 
resident in the south of the country, to have a history of 
blood transfusion, i.v. drug use, unsafe sex, use of glass 
syringes or light alcohol use and to have a lower 
education level. Independent predictors of dual infection 
were age >42 years, history of i.v. drug use (IDU), blood 
transfusion and residence in the south of the country. 
Liaw [17] identified risk factors for HCV superinfection in 
23 hepatitis B patients including blood transfusion, IDU, 
instrumentation and household or community contact. 
Among HIV-infected people, HBV and HCV coinfection 
was as high as 66% (80 of 133) and coinfection was seen 
more frequently in drug users (84%) in comparison with 
the patients infected by homosexual (66%) or heterosexual 
(20%) route [14]. Totally, the risk factors of dual infection 
are similar to those of single infection of the two viruses, 
including IDU, blood transfusion, unsafe sexual contact, 
and other parenteral transmission modes and IDU and 
blood transfusion are the two major modes which account 
for nearly 90% of dual infection. 
Table 1. Prevalence of serum anti-HCV-positive in HBsAg-
positive patients with chronic liver diseases 
Anti-HCV  Geographic 
Area 
Year Author No. 
No. % 
Reference 
China   1999  Chen  712  103  14.47  [1] 
 1994  Li  193  22  11.39  [2] 
Japan 1994 Sato 82  18  23  [3] 
 1994  Ohkawa  156  20  12.8  [4] 
Taiwan 1994 Liaw 1498  173  12  [5] 
 1991  Chan  323  11  3.4    [6] 
Italy 2003  Gaeta  837  59  7  [7] 
 1999  Di  Marco  302  43  14.2  [8] 
 1991  Fattovich  184  27  15  [9] 
Spain 1994  Crespo  132  17  13  [10] 
3.  Clinical feature of coinfection with HBV and HCV 
Simultaneous HBV and HCV Infection in Acute Hepatitis 
Because the patients with HBV and HCV acute 
coinfection are limited and only a few reports are 
available, little is known about this aspect. Five patients 
with acute HBV and HCV coinfection observed by 
Mimms have a lower level of HBsAg and ALT as 
compared with patients with acute HBV infection alone, 
and four of them developed chronic HCV infection [18]. 
The result indicated that onset of hepatitis B may reduce 
the severity of HCV infection but not frequency of 
chronicity. Similar to this study, Sagnelli [19] reported 3 
patients with acute HBV and HCV coinfection recovered 
from HBV infection and progressed to HCV-related 
chronic hepatitis and none of the 3 patients had a severe 
form of acute hepatitis. However, Chu and Liaw [20] have 
described a serologically and virologically proven case of 
acute HCV and HBV coinfection presenting as biphasic 
ALT elevation with fulminant hepatitis. Furthermore, 
Alberti [21] studied 30 patients with symptomatic acute 
hepatitis in whom markers of active HBV and HCV 
infection were found to coexist. All patients were Int. J. Med. Sci. 2006, 3  58
observed during the acute hepatitis and were followed for 
a long time after acute hepatitis, and their clinical features 
and outcome were compared with those of patients 
suffering from acute hepatitis due to single HBV and HCV 
infection. The acute phase peak in transaminase activity 
was particularly high in patients with mixed HBV and 
HCV infection, but chronicity rates of hepatitis B and of 
hepatitis C were not modified, and were similar to those 
of patients with single infection. When individual patients 
were monitored during the acute phase, at least two 
distinct peaks of alanine aminotransferase (ALT) were 
observed in patients with dual infection, independently of 
whether hepatitis then resolved or progressed to 
chronicity. 
From above, coinfection of HBV and HCV in acute 
hepatitis will progress to HCV-related chronic hepatitis 
and the chronicity rates are not modified, but the severity 
of hepatitis in patients with dual infection is not 
accordance in these studies. 
HBV and HCV Coinfection in Patients with Chronic 
Liver Diseases 
Although dual infection with HBV and HCV leads to 
mutual suppression of both viruses, several studies have 
suggested that multiple HBV and HCV infection may be 
associated with more severe clinical presentation [9,10]. A 
Saudi Arabia study [22] showed that the patients with 
dual HCV and HBV infection had more decompensated 
liver disease. Most of these patients were classified in the 
Child-Pugh group C as compared to the controls (36.8% 
vs 0%, p < 0.01). Markedly different anti-HCV positive 
rates (P < 0.001) in hepatitis B patients in different clinical 
stages were discovered in a study from China [23]. The 
anti-HCV positive rate increased with severity of hepatitis 
in those patients. The suggestion that dual infection of 
HBV and HCV may enhance the severity of hepatitis was 
also supported by histological evidence. Zarski [24] 
compared the histological characteristics of patients with 
chronic hepatitis B and C with those of patients with 
chronic hepatitis C alone. Histological lesions were more 
severe in dual infection than in HCV single infection, 
including prevalence of cirrhosis, knodell score and 
piecemeal necrosis and fibrosis. In an Italian multicenter 
case-control study [25], the clinical impact of multiple 
virus infection was compared with a single HBV or HCV 
infection. Moderate or severe chronic hepatitis or cirrhosis 
were more frequent in patients with HBV and HCV 
coinfection (62.9% of 65 patients) than in patients with 
HBV infection (46.7% of 90, P<0.05) or patient with HCV 
infection (40.8% of 98, P<0.005). These data showed that 
HBV and HCV dual infection increased the severity of 
histological lesions. 
HCV Superinfection in Individuals with Chronic HBV 
Infection 
Acute HCV superinfection in HBsAg carriers may be 
the major cause of fulminant/subfulminant hepatitis. Two 
independent studies from Taiwan [26, 27] have showed 
that a significant proportion of fulminant/subfulminant 
hepatitis in chronic HBsAg carriers could be attributed to 
HCV superinfection. Moreover, Chu et al [28] conducted a 
study to investigate the risk of fulminant hepatitis C in 
relation to concurrent infection of HBV. Of 109 patients 
with acute hepatitis C, 11 patients (10.1%) had the 
complication of FHF. The occurrence of fulminant hepatic 
failure (FHF) was closely related to concurrent HBV 
chronic infection. The incidence of FHF in patients with 
underlying chronic HBV infection was 23.1% (9/39), 
which is significantly higher than in those without (2.9% 
or 2/70). Recently, Liaw et al [17] studied the natural 
course following acute HCV superinfection in HBV 
infection. In this study, acute HCV superinfection in 
patients with chronic HBV infection is clinically severe 
during acute phase. Moreover, during a follow-up period 
of 1-21 years, patients with acute superinfection had a 
significantly higher cumulated incidence of cirrhosis (48% 
at 10 years) and HCC (14% at 10 years, 21% at 15 years, 
and 32% at 20 years) than acute HDV superinfection or 
active chronic hepatitis B. Generally, HCV superinfection 
can cause a much more severe liver disease in patients 
with chronic HBV infection. 
HBV Superinfection in Individuals with HCV Infection 
A few case reports suggest the association between 
HBV superinfection in HCV infection and severe clinical 
presentation [29,30]. A recent report investigated on the 
clinical presentation of HBV superinfection in HCV 
chronic carriers [31]. A severe clinical presentation 
(development of portosystemic encephalopathy or ascites 
or prothorombin activity lower than 25%) was observed in 
6 (28.6%) patients in the patients with HBV superinfection 
in HCV chronic hepatitis and in none of those in the 
control group (patients with HBV infection alone). One of 
these 6 patients had fulminant hepatitis and died within a 
few days because no liver was available for 
transplantation. The study lends support to the notion 
that HBV superinfection may also aggravate the disease 
severity and increase the risk of fulminant hepatitis. All 
together, HBV and HCV dual infection, whether HBV on 
HCV or HCV on HBV, are characterized by a severe 
clinical and histological presentation. 
Occult HBV Infection in Patients with HCV Infection  
Occult HBV infection has frequently been identified 
in patients with HCV-related chronic hepatitis. 
Considerable data suggested that occult infection may 
contribute to chronic liver damage and the development 
of HCC [32, 33, 34, 35]. Cacciola [36] studied the 
prevalence and clinical significance of occult HBV 
infection in patients with chronic hepatitis C. The result 
showed that 21 of the 66 patients with HCV infection and 
occult HBV infection (33%) had cirrhosis, as compared 
with 26 the 134 patients with HCV infection and no occult 
HBV infection (19.8%, p=0.04). This suggests that occult 
HBV infection may interfere with the clinical outcome of 
chronic hepatitis C and favor or accelerate the evolution to 
cirrhosis. Sagnelli [25] suggested that anti-HCV positive, 
anti-HBc-positive patients who lack both HBsAg and anti-
HBs might be a group of patients with a multiple HBV 
and HCV infection. HBV DNA by PCR was detected in 
40.8% of 71 such patients in this study, which implies that 
nearly half of such patients could be classified as occult 
HBV infection. The clinical presentation in patients with 
anti-HCV-positive and anti-HBc-positive was as severe as 
in patients with dual HBV and HCV infection. This means 
that like dual HBV and HCV infection, occult HBV 
infection in chronic hepatitis C could also aggravate the 
disease severity.  
4.  Virus Interaction 
The interaction between HBV and HCV in 
coinfection patients has been investigated in clinical study 
and in vitro experiment. Suppression of HBV replication Int. J. Med. Sci. 2006, 3  59
by HCV in acutely or chronically infected patients is well-
described phenomenon. In vivo study in chimpanzees 
showed that acute HCV superinfection in chronic HBV 
infection resulted in marked reduction in the titer of 
serum HBsAg [37,38]. In clinical studies, the inhibition of 
HBV replication by HCV was also observed [25,39, 40]. 
Serum HBVDNA was found more frequently in patients 
with HBsAg+ /anti-HCV – than in patients with HBsAg+ 
/anti-HCV+ [25] and HBVDNA levels was lower in 
coinfections than in single infections [41]. Liaw et al [42] 
found that HCV infection might suppress HBV or even 
eliminate HBV and become sole cause of persistent 
hepatitis or ALT/AST elevation in a small number of 
patients. In a follow-up study of chronic HBV infection 
[42], the role of HCV in continuing hepatitis after 
termination of chronic HBsAg antigenemia was explored 
in a series of patients. Among 41 patients with persistent 
ALT elevation, 26 were seropositive for anti-HCV. Of 
those seropositive for anti-HCV, serum HBVDNA was not 
detectable, and serum HCVRNA was detected in 23 of the 
26 hepatitis patients. Liver biopsy in 6 anti-HCV positive 
patients with continuing hepatitis showed features 
compatible with chronic hepatitis C. HCVRNA, but not 
HBVDNA, was detected in liver tissues of these 6 patients. 
The results provide direct evidence to confirm that HCV 
superinfection in patients with chronic HBV infection may 
not only terminate chronic HBsAg antigenemia but may 
ever usurp the role of HBV in chronic hepatitis to cause 
continuing ALT elevation. 
The mechanisms accounting for the suppression of 
HCV on HBV were investigated by Shih et al [43]. Their 
findings suggest that HCV may directly interfere with 
HBV replication and furthermore identified the HCV core 
protein as a repressor of HBV production. They found a 
moderate 2-4 fold reduction of HBV mRNA and HBV 
antigen expression in the presence of HCV structure genes 
and a stronger up to 20 fold suppression of HBV particle 
secretion. Furthermore, the target structure of HCV core 
protein was identified in another study [44]. The results 
showed that full-length HCV core protein suppressed the 
HBV enhancer 1 up to 11-fold, the enhancer 2 3-4-fold. 
Suppression of HBV enhancer 1 by HCV core from 
genotype 1b was stronger than by HCV core of genotypes 
3a or 1a. This trans-repression may contribute to 
suppression of HBV replication in patients coinfected with 
both viruses. However, until now it has been completely 
uncertain if or how HCV core may be released from the 
replication/translation complex of HCV, which is a 
prerequisite for the many reported in vitro activities of 
isolated core expression systems. 
The inhibition exerted by HBV on the HCV genome 
also has been shown in chronic HBV/HCV concurrent 
infection. Zarski et al [24] compared virological 
characteristics of patients with chronic hepatitis B and C 
with those of patients suffering from chronic C alone. The 
results suggest an inverse relationship between the 
replicative patterns of both viruses. The HCV RNA level 
was significantly decreased in HBV DNA positive patients 
compared with HBVDNA negative patients. An Italian 
multicenter case-control study [25] was performed on a 
high number of patients with chronic hepatitis from a 
multiple hepatitis virus infection who were compared 
with patients with chronic hepatitis caused by a single 
virus. In this study, HCVRNA was detected more 
frequently in patients with anti-HCV positive (90.7% of 
130) than in patients with HBsAg/anti-HCV positive 
(65.2% of 69, p<0.001). 
5.  Antivirus Therapy 
Few data exist on treatment of double infection. 
Some preliminary studies [45,46] showed that patients 
with dual HBV and HCV infection had responded poorly 
to interferon (IFN) monotherapy. In an open trial of the 
efficacy of interferon-alpha 2b (IFN-alpha) treatment on 
multiple infection, eight patients with chronic HBV and 
HCV were treated with recombinant IFN-alpha 2b [3 
million units (MU), thrice weekly for 6 months]. Liver 
function tests normalized in two patients and one lost 
hepatitis B surface antigen (HBsAg) [45]. Silent HBV 
coinfection with HCV decreases the response to 
interferon. Sagnelli [47] reported that fewer patients with 
chronic hepatitis C and isolated anti-HBc have a sustained 
response to interferon-alpha treatment than those with 
chronic hepatitis C (7.8% vs. 30.4%, p=0.009). Similar 
results have been observed by others in patients having 
silent HBV coinfection with HCV [48]. 
It has been suggested that a specific dose and 
duration of IFN regimen for the treatment of either HBV 
or HCV should be chosen based on which viral infection is 
determined to be active. In the attempt to verify whether 
the outcome of IFN therapy in patients with hepatitis B 
and hepatitis C coinfection can be improved, Villa [49] 
conducted a prospective, randomized trial with medium 
to high dosages of interferon three times a week for 6 
months. Thirty patients with HBV-HCV coinfection, and 
chronic hepatitis were randomized to receive either 6 or 9 
MU alpha-interferon three times a week for 6 months. 
Five patients treated with 9 MU IFN consistently cleared 
HCV RNA and HBV DNA, whereas none of those treated 
with 6 MU reacted in a similar fashion (p = 0.045). 
Responders showed significant improvement of 
histological activity index in comparison with non-
responders (mean Ishak score pre-treatment versus post-
treatment p = 0.002). Long term follow-up showed that 
none of the patients treated with high doses developed 
cirrhosis whereas 4/14 treated with low doses did 
develop cirrhosis. The results indicate that with HBV-
HCV coinfection, a trial with high doses of interferon is 
strongly recommended. Recently, Chuang [50] conducted 
a case-control study to investigate the efficacy of 
interferon-alpha (IFN-alpha) and ribavirin combination 
therapy for patients with chronic hepatitis C and B virus 
(HCV/HBV) coinfection. Forty-two chronic HCV/HBV-
coinfected patients (29 IFN-naive, 13 IFN-relapsed) and 84 
HCV-monoinfected controls, matched for age, sex and 
previous history of IFN-alpha therapy, were enrolled. All 
patients were treated with IFN-alpha-2b 6 MU three-times 
weekly plus ribavirin 1000-1200 mg daily for 24 weeks. 
The rate of HCV sustained virological response (SVR) was 
comparable among IFN-naive and IFN-relapsed 
HCV/HBV-coinfected patients and IFN-naive and IFN-
relapsed HCV-monoinfected patients (69.0%, 69.2%, 67.2% 
and 57.7%, respectively; intention-to-treat analysis). Of 16 
baseline HBV viraemic patients, five (31.3%) achieved 
HBV SVR, which correlated negatively to HCV genotype 
non-1b and HCV SVR. Only one (6.3%) had simultaneous 
seroclearance of HCV and HBV.  The author suggested 
that IFN-alpha/ribavirin combination therapy was 
effective for HCV/HBV-coinfected patients in eradicating 
HCV infection and might promote HBV seroclearance. Int. J. Med. Sci. 2006, 3  60
6.  Dual Infection of HBV and HCV and 
hepatocellular carcinoma (HCC) 
HBV and HCV infections are confirmed causes of 
HCC. What’s the combined effect of HBV and HCV 
coinfection on HCC? Accumulated epidemiological data 
suggested that coinfection with HBV and HCV could 
increase the risk for development of HCC. A case-control 
study [51] conducted in Qidong county (a higher 
incidence area of HCC in China) showed that the OR 
values for HCC were similar in patients with HBV (3.90) 
and HCV (3.89) infection, and highest in coinfection with 
HBV and HCV (6.48, see Table 2). In a prospective study 
in Italy [52], 290 consecutive patients with cirrhosis were 
followed up. During a follow-up of 8-96 months, HCC 
was observed in 12.2% of anti-HCV-positive patients, in 
19.6% of HBsAg-positive patients, and in 40.0% of patients 
with dual HBsAg and anti-HCV positive. To clarify the 
roles of HBV and HCV on the risk for HCC, a case-control 
study was conducted by Kirk in Gambia [53], a small 
country in West Africa where HCC is the most frequent 
cause of cancer death among men. In a multivariable 
logistic regression model, the HCC risk was similar 
(OR16.7), with only HBsAg or with only anti-HCV. HCC 
risk with dual HBsAg and anti-HCV (OR, 35.3) was nearly 
equal to that expected with an additive statistical 
interaction, but did not approach that expected with a 
multiplicative interaction. 
Several studies have shown that patients with HCC 
who have antibody to HCV often possess HBV related 
serological markers [54,55,56]. Marusawa [57] have looked 
for the presence of seralogical markers of HBV in a large 
cohort of 2014 HBsAg negative Japanese patients with 
HCV infection. A large number of patients (49.9%) with 
HCV related chronic liver disease including HCC were 
positive for anti-HBc. Patients with HCC were 
significantly more likely to have evidence of previous 
HBV infection than patients with either cirrhosis or 
chronic hepatitis. These data suggest that HBV infection, 
probably including latent infection, may play an 
important role in carcinogenesis in the patients with HCV 
infection. 
Table 2. Coinfection with HBV and HCV and risk of HCC 
 HCC case  Variables Case  number 
No. % 
OR 95%CL 
HBV(-)HCV(-)  118  13  11.2  1.00       --- 
HBV(+)HCV(-) 184 79  42.9  3.90  2.49-6.11 
HBV(-)HCV(+)  7  3  42.8 3.89 1.31-11.53 
HBV(+)HCV(+)  21  15  71.4 6.48 3.53-11.89 
7.  Research Direction 
New antiviral agents such as peginterferon, adefovir 
and entecavir have been licensed for treatment of patients 
with HCV or HBV. However, until now there is no 
standard of care available for treatment of patients with 
coinfection. Further clinical trails are needed to clarify the 
optimal treatment for such patients. Moreover, HCV 
genotype and HBV genotype were found to be associated 
with clinical outcome in single infection in many 
epidemiological studies. What is the role of genotype of 
HBV and HCV in the setting of coinfection? As for 
interaction between the two viruses, the mechanism of 
mutual inhibition is still unclear, especially for the 
suppression of HCV by HBV. Future research should 
focus on these issues. 
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